Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth

1. CEO Jay Backstrom discussed apitegromab for spinal muscular atrophy at J.P. Morgan. 2. Company plans U.S. and European marketing applications by Q1 2025. 3. Apitegromab projected to generate over $2 billion in global revenue. 4. JP Morgan maintains an Overweight rating on Scholar Rock, citing strong SAPPHIRE results. 5. Details from the phase 2 EMBRAZE trial expected in Q2 2025.